Takeda discontinuing in AAV and rare haematology disease markets
Pharmaceutical Technology
APRIL 13, 2023
The company is aiming to refocus its efforts on its core therapeutic areas and current late-stage programmes such as the oral TYK2 inhibitor TAK-279, which is under development for several autoimmune disorders.
Let's personalize your content